Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound
JE · Effective Nov 12, 2023
29 active Medicare policies list M62.830, and 4 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
JE · Effective Nov 12, 2023
JF · Effective Nov 12, 2023
JJ · Effective Apr 30, 2023
JM · Effective Apr 30, 2023
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JE · Effective Oct 1, 2015
JF · Effective Oct 1, 2015
J9 · Effective Oct 1, 2015
4 policies from 1 payer
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of M62.830 |
|---|---|---|
| Botulinum Toxin | Jan 1, 2024 | Covered |
| Spasticity Management | Jun 21, 2023 | Covered |
| Standing Frames, Tables, and Transfer Boards | Jun 19, 2023 | Covered |
| Surface Scanning and Macro Electromyography | Mar 22, 2023 | Covered |
JH · Effective Oct 1, 2015
JL · Effective Oct 1, 2015
National · Effective Oct 23, 2025
J6 · Effective Oct 1, 2025
National · Effective Oct 1, 2025
J5 · Effective Oct 1, 2025
J9 · Effective Jan 1, 2026
JL · Effective Jan 1, 2026
National · Effective Jan 1, 2026
National · Effective Aug 28, 2025
National · Effective Jan 1, 2026
National · Effective Jan 1, 2026
National · Effective Oct 1, 2025
National · Effective Jan 1, 2026
National · Effective Oct 23, 2025
JL · Effective Oct 1, 2025
J9 · Effective Oct 1, 2025
National · Effective Jan 1, 2026
National · Effective Jan 1, 2026
National · Effective Oct 1, 2025